SELLAS Life Sciences estimates $71.8M cash at Dec 31, 2025; $26.5M from warrant exercises post-quarter

SELLAS Life Sciences Group, Inc.

Cash and cash equivalents estimate of $71.8M as of Dec 31, 2025 (unaudited, preliminary).
Received ~$26.5M in proceeds from common stock warrant exercises subsequent to year-end.
As of Jan 7, 2026, shares outstanding total 170,282,026.
No other operational or financial results disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.